Formal topical drug interaction studies with tacrolimus ointment have not been conducted.
Tacrolimus is not metabolized in human skin, indicating that there is no potential for percutaneous interactions that could affect the metabolism of tacrolimus.
A potential interaction between vaccination and application of tacrolimus ointment has not been investigated because of the potential risk of vaccination failure.
Vaccination should be administered prior to commencement of treatment or during a treatment free interval with a period of 14 days between the last application of tacrolimus and the vaccination. In case of attenuated vaccination, this period should be extended to 28 days or the use of alternative vaccines should be considered.